<DOC>
	<DOCNO>NCT00546533</DOCNO>
	<brief_summary>To assess efficacy etanercept 25 mg administer subcutaneously twice-weekly 12 week patient active RA classical antirheumatic therapy insufficient inappropriate .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>A negative serum urine pregnancy test screen medically acceptable form contraception start screen continue throughout study require female childbearing potential ( defined oral , injectable , implantable contraceptive , intrauterine device , barrier method combine spermicide ) . Failed therapy least one DMARD ( DMARD failure define discontinuation lack clinical efficacy ) . Meet 1987 American Rheumatism Association ( ARA ) revise criterion rheumatoid arthritis . Uncooperative patient history poor compliance . Known hypersensitivity etanercept component . Known significant concurrent medical disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>